GD Lifescience
Annual accounts 2025
micro format, filed on 24-06-2026, 37 days before the deadlineTurnover and EBIT margin are not published. The micro format does not require them. The turnover shown is an estimate from the gross margin.
Turnover ≈ €1.0m. Estimated: probably between €840,000 and €1.8m.
Balance sheet
balance sheet total €935,202 on 31-12-2025in euro
in euro
Position in the sector
56.1%
Higher than 51% of 41,228 companies in 2025.
1.87
Higher than 46% of 39,797 companies in 2025.
53.9%
Higher than 89% of 40,318 companies in 2025.
Net result: top quarter · Equity: top quarter · Balance sheet total: top quarter · Working capital: top quarter
Filed annual accounts
as filed with the National Bank, click a year to choose it| Line | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Balance sheet: assets | |||||||
20/58 |
935,202 | 803,775 | 641,091 | 434,614 | 311,535 | 213,146 | |
21/28 |
172,682 | 177,318 | 172,866 | 118,335 | 61,710 | - | |
22/27 |
4,248 | 8,884 | 4,432 | 5,498 | 2,875 | - | |
23 |
- | 8,884 | 4,432 | 5,498 | 2,875 | - | |
24 |
4,248 | - | - | - | - | - | |
28 |
168,434 | 168,434 | 168,434 | 112,837 | 58,834 | - | |
29/58 |
762,521 | 626,457 | 468,225 | 316,279 | 249,826 | 213,146 | |
29 |
113,406 | 113,406 | 113,406 | 63,406 | 30,000 | 30,000 | |
291 |
113,406 | 113,406 | 113,406 | 63,406 | 30,000 | 30,000 | |
40/41 |
19,056 | 313,247 | 96,529 | 51,765 | 121,214 | 14,200 | |
40 |
13,656 | 247,526 | 40,066 | 49,365 | 106,292 | - | |
41 |
5,400 | 65,721 | 56,463 | 2,400 | 14,922 | 14,200 | |
54/58 |
622,998 | 192,744 | 251,230 | 194,048 | 95,206 | 168,946 | |
490/1 |
7,060 | 7,060 | 7,060 | 7,060 | 3,406 | - | |
| Balance sheet: equity and liabilities | |||||||
10/49 |
935,202 | 803,775 | 641,091 | 434,614 | 311,535 | 213,146 | |
10/15 |
524,259 | 523,572 | 239,191 | 393,252 | 271,236 | 163,183 | |
10/11 |
20,000 | 20,000 | 20,000 | 20,000 | 20,000 | 20,000 | |
14 |
504,259 | 503,572 | 219,191 | 373,252 | 251,236 | 143,183 | |
17/49 |
410,943 | 280,203 | 401,900 | 41,362 | 40,299 | 49,963 | |
42/48 |
408,556 | 277,815 | 396,993 | 37,827 | 37,209 | 49,963 | |
44 |
5,002 | 97,161 | 1,052 | 4,322 | 1,745 | 847 | |
440/4 |
5,002 | 97,161 | 1,052 | 4,322 | 1,745 | 847 | |
45 |
214,967 | 180,655 | 130,942 | 29,795 | 34,927 | 3,500 | |
450/3 |
214,967 | 180,655 | 130,942 | 29,795 | 34,927 | 3,500 | |
47/48 |
188,587 | 0 | 265,000 | 3,710 | 536 | 45,616 | |
492/3 |
2,388 | 2,388 | 4,906 | 3,535 | 3,091 | - | |
| Income statement | |||||||
76A |
- | 0 | 1,425 | - | - | - | |
9900 |
706,148 | 382,695 | 147,874 | 158,069 | 138,044 | 195,667 | |
630 |
4,636 | 3,111 | 2,468 | 1,519 | 300 | - | |
640/8 |
7,304 | 6,137 | 446 | 2,252 | 53 | 120 | |
9901 |
694,208 | 373,447 | 144,959 | 154,298 | 137,691 | 195,547 | |
75/76B |
3,957 | 10,829 | 15,688 | 9,461 | 4,657 | 1,200 | |
75 |
3,957 | 10,829 | 15,688 | 9,461 | 4,657 | 1,200 | |
65/66B |
16,809 | 8,499 | 5,708 | 3,890 | 3,217 | 1,564 | |
65 |
16,809 | 8,499 | 5,708 | 3,890 | 3,217 | 1,564 | |
9903 |
681,357 | 375,776 | 154,939 | 159,869 | 139,131 | 195,183 | |
67/77 |
177,170 | 91,395 | 44,000 | 37,853 | 31,078 | 52,000 | |
9904 |
504,187 | 284,381 | 110,939 | 122,017 | 108,053 | 143,183 | |
9905 |
504,187 | 284,381 | 110,939 | 122,017 | 108,053 | 143,183 | |
| Appropriation of the result | |||||||
9906 |
1.0m | 503,572 | 484,191 | 373,252 | 251,236 | 143,183 | |
14P |
503,572 | 219,191 | 373,252 | 251,236 | 143,183 | - | |
694/7 |
503,500 | 0 | 265,000 | - | - | - | |
694 |
503,500 | 0 | 265,000 | - | - | - | |
| Document | |||||||
The notes to these accounts have 9 items, including the statement of assets and debts, the cost breakdown and rights and commitments. You find them in the accounts filed with the NBB.
Source: Annual accounts 2025 at the NBB, filed on 24-06-2026.
Filings
each dot is a set of accounts, on the day it reached the National Bank| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 31-12-2025 | micro format | 24-06-2026 | 2026-00190925 | |
| 31-12-2024 | micro format | 24-07-2025 | 2025-00304816 | |
| 31-12-2023 | micro format | 01-07-2024 | 2024-00187558 | |
| 31-12-2022 | micro format | 22-06-2023 | 2023-00150073 | |
| 31-12-2021 | micro format | 22-06-2022 | 2022-20080728 | |
| 31-12-2020 | micro format | 15-07-2021 | 2021-36500361 |
Key figures and ratios
per financial year, computed from the annual accounts| Line | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| 698,844 | 376,558 | 147,428 | 155,817 | 137,991 | - | ||
| 508,823 | 287,492 | 113,407 | 123,536 | 108,352 | - | ||
| 0 | 7,564 | 57,000 | 58,144 | 62,009 | - | ||
| 430,254 | -58,486 | 57,182 | 98,842 | -73,740 | - | ||
| 353,965 | 348,642 | 71,232 | 278,452 | 212,617 | 163,183 | ||
| 56.1% | 65.1% | 37.3% | 90.5% | 87.1% | 76.6% | ||
| 1.87 | 2.25 | 1.18 | 8.36 | 6.71 | 4.27 | ||
| 0.78 | 0.54 | 1.68 | 0.11 | 0.15 | 0.31 | ||
| 96.2% | 54.3% | 46.4% | 31.0% | 39.8% | 87.7% | ||
| 53.9% | 35.4% | 17.3% | 28.1% | 34.7% | 67.2% | ||
| 41.58 | 44.30 | 25.83 | 40.06 | 42.90 | - |
A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.
Investments
fixed assets acquired| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tangible fixed assets | - | €7,564 | €1,402 | €4,142 | €3,175 |
| Financial fixed assets | €0 | - | €55,597 | €54,002 | €58,834 |
| €4,636 | €3,111 | €2,468 | €1,519 | €300 |
Source: notes to the 2021 to 2025 annual accounts (statement of fixed assets)
Insights on GD Lifescience
The operating result for 2025 is 86% higher than in 2024 and the highest since 2020. It is the second rise in a row, after the fall in 2023.
Debt's share of the balance-sheet total rises from 34.9% to 43.9%. Equity and debt are higher.